[Transcranial magnetic stimulation in the treatment of depressive disorder in Parkinson's disease].

Autor:	Prosvetov AO; Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia., Tsygankov BD; Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia., Guekht AB; Moscow Research and Clinical Center for Neuropsychiatry, Moscow, Russia., Kuznetsov EV; Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia., Less UE; Moscow Research and Clinical Center for Neuropsychiatry, Moscow, Russia., Tumurov DA; Moscow Research and Clinical Center for Neuropsychiatry, Moscow, Russia., Popov GR; Moscow Research and Clinical Center for Neuropsychiatry, Moscow, Russia., Tsygankov DB; Institute of Mental Health and Addictology, Moscow, Russia., Rangus SR; Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2022; Vol. 122 (9), pp. 79-85.
DOI:	10.17116/jnevro202212209179
Abstrakt:	The prevalence of affective disorders in patients with Parkinson's disease (PD) is significantly higher than in the general population of people of the same age. It is known that the effectiveness of antidepressants in PD with depressive disorder is lower than in patients with primary depression. For depression resistant to standard treatments, other therapeutic strategies are available. Transcranial magnetic stimulation (TMS) is one of the most popular and safe brain stimulation methods that has been successfully used to treat primary depression. The accumulation of experience in the use of TMS has made it possible to expand the application of the method to other diseases, including PD. The article provides literature data on the use of different TMS protocols for the treatment of depressive disorder in patients with PD.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu